Search Results
Your search for ,had matches 18604 pages
Showing 11851 - 11900Second Cancers May Be Deadlier in Pediatric, Adolescent, and Young Adult Patients
Second cancers in children as well as adolescents and young adults (AYAs) are far deadlier than they are in older adults and may partially account for the relatively poor outcomes of cancer patients aged 15 to 39 years overall, according to a new study by University of California (UC), Davis...
FDA Expands Approved Use of Regorafenib for Hepatocellular Carcinoma
The U.S. Food and Drug Administration (FDA) has expanded the approved use of regorafinib (Stivarga) to include treatment of patients with hepatocellular carcinoma who have been previously treated with the drug sorafenib (Nexavar). This is the first new FDA-approved treatment for liver cancer in...
ELCC 2017: Patients With Lung Cancer Treated With PD-1/PD-L1 Checkpoint Inhibitors May Experience Adverse Events After Influenza Vaccination
Patients with lung cancer treated with programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) checkpoint inhibitors may be at increased risk of adverse events after receiving the seasonal influenza vaccination, according to the first study measuring this effect. The results, to ...
Clinical Practice Guidelines on the Evidence-Based Use of Integrative Therapies During and After Breast Cancer Treatment
In newly updated clinical guidelines from the Society for Integrative Oncology (SIO), researchers at Columbia University's Mailman School of Public Health and the Herbert Irving Comprehensive Cancer Center, along with an interdisciplinary team of colleagues at The University of Texas MD Anderson...
Long-Term Outcome With Combined-Modality vs Systemic Treatment for Unresectable Colorectal Liver Metastases
The long-term follow-up of a phase II trial reported by Ruers et al in the Journal of the National Cancer Institute showed a 42% reduced risk of death among patients with colorectal liver metastases receiving aggressive local treatment plus systemic therapy vs systemic therapy alone. Study Details ...
ILC 2017: Selective Internal Radiation Therapy vs Sorafenib in Hepatocellular Carcinoma
Results of the SARAH trial presented at the 2017 International Liver Congress (ILC) demonstrated that selective internal radiation therapy (SIRT) resulted in a median overall survival of 8.0 months compared to 9.9 months with sorafenib (Nexavar; P = .179) in patients with locally advanced ...
Reduced-Dose Radiotherapy for HPV-Positive Oropharyngeal Carcinoma
A phase II trial conducted at the University of California at Davis and at Los Angeles showed good outcomes with reduced-dose radiotherapy in patients with human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma. These findings were reported in The Lancet Oncology by Chen et al....
Prophylactic Cranial Irradiation vs Observation in Extensive-Disease Small Cell Lung Cancer
A Japanese phase III trial has shown no survival benefit of prophylactic cranial irradiation vs observation in patients with extensive-disease small cell lung cancer who had any response to platinum-based doublet chemotherapy and no brain metastases at baseline. These findings were reported in The...
Long-Term Outcome With Combined-Modality vs Systemic Treatment for Unresectable Colorectal Liver Metastases
The long-term follow-up of a phase II trial reported by Ruers et al in Journal of the National Cancer Institute showed a 42% reduced risk of death among patients with colorectal liver metastases receiving aggressive local treatment plus systemic therapy vs systemic therapy alone. Study Details...
Noninvasive Imaging Test May Accurately Rule Out Kidney Cancers
The latest in a series of studies led by researchers at Johns Hopkins Medicine shows that addition of a widely available, noninvasive imaging test called 99mTc-sestamibi SPECT/CT (single-photon emission computed tomography plus computed tomography) to conventional CT or magnetic resonance imaging...
Neoadjuvant Chemotherapy for Breast Cancer and Risk for Local Metastases
A pathologic complete response to presurgical therapy occurs in between 40% and 50% of patients with HER2-positive and triple-negative breast cancer, raising the question of the need for surgery for all patients after neoadjuvant chemotherapy indicates a pathologic complete response in...
Racial/Ethnic Disparities in End-of-Life Care for Patients With Ovarian Cancer
A study using linked Texas Cancer Registry–Medicare data has identified racial/ethnic disparities in end-of-life care in women with ovarian cancer. The study was reported by Taylor et al in the Journal of Clinical Oncology. Study Details The study included 3,666 patients dying in 2000 to...
Low Cervical Cancer Screening Rates Found Among Women With Severe Mental Illness
Women enrolled in California's Medicaid program (Medi-Cal) who have been diagnosed with severe mental illness have been screened for cervical cancer at much lower rates than other women, according to a new study by researchers at the University of California, San Francisco (UCSF), published by...
Efficacy Analysis of ABC Breast Cancer Trials of Adjuvant Taxane With/Without Anthracycline in HER2-Negative Disease
As reported by Blum et al in the Journal of Clinical Oncology, the efficacy analysis of the combined adjuvant Anthracyclines in Early Breast Cancer (ABC) Trials showed better invasive disease-free survival with taxane plus doxorubicin/cyclophosphamide (TaxAC) regimens vs six cycles of...
Metastatic Uveal Melanoma Response to Adoptive Transfer of Autologous Tumor-Infiltrating Lymphocytes
As reported by Chandran et al in The Lancet Oncology, a single-center study has shown that adoptive transfer of autologous tumor-infiltrating lymphocytes produces tumor responses in metastatic uveal melanoma. Study Details The study involved 21 consecutive patients treated at the Surgery Branch...
Higher Rates of Bone Metastases and Increased Risk of Death in Follicular and Medullary Thyroid Cancer
In the largest-known study on bone metastases in thyroid cancer, researchers at the University of Michigan Comprehensive Cancer Center found that patients with follicular and medullary thyroid cancer had the highest rate of cancer-related bone lesions and fractures and an increased risk of death....
Predictors of Adherence to Oral Chemotherapy
In a single-center study reported in the Journal of Oncology Practice, Jacobs et al found that improved satisfaction with clinician communication and treatment was the strongest predictor of treatment adherence in patients receiving oral anticancer medication. Study Details The prospective study...
Pigmented Vascular Tumor
Nevus Vasculaire Albumen Print, Paris, 1869 Published in 1869, Revue Photographique des Hôpitaux de Paris was the world’s first medical journal to contain real photographs. In the seven issues produced between 1869 and 1875, 245 images were used. Dr. A. de Montméja, a Parisian ophthalmologist and...
Study Associates Comorbidities With Survival Outcomes in Women With Ovarian Cancer
Research from epidemiologists at Roswell Park Cancer Institute, published by Minlikeeva et al in Cancer Causes & Control, suggests that hypertension and diabetes and the use of medications to treat these comorbidities may have an effect on survival outcomes in women with ovarian cancer. Study...
Update to ASCO Clinical Practice Guideline on Potentially Curable Pancreatic Cancer
An ASCO clinical practice guideline update, reported by Khorana et al in the Journal of Clinical Oncology, includes the recommendation of gemcitabine-capecitabine doublet therapy as an adjuvant therapy option in potentially curable pancreatic cancer. The updated recommendation (4.1) modifies the...
More on Treatment Decisions in Esophageal Cancer
In the March 25, 2017, issue of The ASCO Post, Steven H. Lin, MD, PhD, shared his thoughts on the role of positron-emission tomography (PET) in assessing response to induction chemotherapy in patients with resectable esophageal or gastroesophageal junction cancer. He noted that complete pathologic...
Addition of Buparlisib to Paclitaxel in Squamous Cell Carcinoma of the Head and Neck
In the phase II BERIL-1 trial reported in The Lancet Oncology, Soulières et al found that adding the pan-PI3K (phosphatidylinositol 3-kinase) inhibitor buparlisib to paclitaxel improved outcomes in patients with platinum-pretreated recurrent metastatic squamous cell carcinoma of the head and neck....
Adding Bevacizumab to Cisplatin/Etoposide in Extensive-Disease Small Cell Lung Cancer
In an Italian phase III trial reported in the Journal of Clinical Oncology, Marcello Tiseo, MD, of Azienda Ospedaliero-Universitaria, Parma, Italy, and colleagues found that adding first-line bevacizumab (Avastin) to cisplatin/etoposide did not prolong overall survival in patients with...
Expect Questions About Continued Risk of Melanoma
Survivors of melanoma are more likely to limit their exposure to ultraviolet radiation than those who have not had the disease, but more than 10% continue to intentionally tan, according to a study published in Cancer Epidemiology, Biomarkers and Prevention.1 The study surveyed 724 people diagnosed ...
Some Melanoma Survivors Continue to Seek Sun Exposure, Risking Second, Potentially More Serious Melanoma
Long-term survivors of melanoma are more likely than those who have not been diagnosed with the disease to use sunscreen, protective clothing, and other means to limit exposure to the sun, according to a survey of melanoma survivors and controls about ultraviolet radiation exposure and protective...
Better Vision Function May Be Related to Better Quality of Life in Patients With Head and Neck Cancer
Better vision function seems to be related to better quality of life after treatment for head and neck cancer, particularly among patients who have had surgery, according to Hsiao-Lan Wang, PhD, RN, Assistant Professor in the College of Nursing at the University of South Florida. Head and neck...
Fear Has Become a Big Part of My Survivorship
Just 32 when I first felt a lump in the top of my left breast, I never expected it to be cancer or my life would irrevocably change in that instant. With no history of breast cancer in my family, I initially shook off any thoughts that I could have a serious disease and instead consoled myself...
Carlo M. Croce, MD, FAACR, Recognized With 2017 AACR Margaret Foti Award
The American Association for Cancer Research (AACR) recognized Carlo M. Croce, MD, FAACR, with the 11th Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research during the AACR Annual Meeting 2017 in Washington, DC. The Margaret Foti Award for Leadership and...
Using Geriatric Assessment Strategies to Inform Patient-Centered End-of-Life Care
End-of-life care in any patient with cancer is challenging for the patient, family, and physician. Issues faced at the end of life include pain, depression, loss of dignity, and hopelessness. In the geriatric patient, additional complexities are present in the form of comorbid conditions,...
Equivalent Response Rates With Trastuzumab or a Trastuzumab Biosimilar Plus Taxane in HER2-Positive Metastatic Breast Cancer
In part 1 of the Heritage study, a phase III equivalence trial reported in JAMA, Hope S. Rugo, MD, of the University of California Helen Diller Family Comprehensive Cancer Center, San Francisco, and colleagues found that treatment with trastuzumab (Herceptin) or a proposed trastuzumab biosimilar...
Accelerating Pediatric Drug Development: Master Protocols May Be a Way to Go
Development of pediatric cancer drugs has long lagged behind adult drug development for two major reasons: The process is more difficult, and childhood cancer is rarer by far than adult cancer. These and other phenomena in pediatric oncology were the subject of a workshop held by the Friends of...
Monoclonal Antibody Therapy With Daratumumab in Multiple Myeloma: Expanding Therapeutic Horizons
The advent of successful monoclonal antibody therapy in the treatment of relapsed/refractory myeloma has dramatically improved the prognosis of patients for whom currently approved novel therapies have failed. In 2015, the approval of the combination of elotuzumab (Empliciti) with lenalidomide...
Adding Daratumumab to Lenalidomide/Dexamethasone Increases Progression-Free Survival in Previously Treated Multiple Myeloma
As reported in The New England Journal of Medicine by Meletios A. Dimopoulos, MD, of the National and Kapodistrian University of Athens, and colleagues, the phase III POLLUX trial has shown that the addition of the CD38-targeted antibody daratumumab (Darzalex) to lenalidomide...
Updated Data on Treatment With Ibrutinib and Venetoclax in Patients With CLL/SLL
Long-term follow-up of treatment with ibrutinib (Imbruvica) in patients with previously untreated and treated chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) has shown high response rates that are durable. At 5 years, 89% of patients with treatment-naive and relapsed or...
Treating Human Immunodeficiency Virus–Related Lymphoma
Alexandra Levine, MD, MACP, is Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, Duarte, California, and has been on the front lines of the AIDS epidemic from the beginning—before the disease even had a name. Dr. Levine spoke with The ASCO Post about ...
Treatment of Diffuse Large B-Cell Lymphoma Continues to Evolve
Although the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) has improved with R-CHOP—the addition of rituximab (Rituxan) to the cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy regimen—one-third of patients still relapse after therapy, and patients with the ...
Nivolumab in Urothelial Carcinoma After Platinum Therapy
On February 2, 2017, nivolumab (Opdivo) was granted accelerated approval for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or after platinum-containing chemotherapy or have disease progression within 12 months of neoadjuvant...
Combination of Atezolizumab and Bevacizumab in PD-L1–Positive Patients With Metastatic Kidney Cancer
The combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) appears to be promising in the first-line treatment of patients with metastatic renal cell carcinoma, according to results of a phase II trial presented at the 2017 Genitourinary Cancers Symposium.1 Despite the failure of the...
CAR T-Cell Therapy Shows Benefit in Patients With Treatment-Resistant Chronic Lymphocytic Leukemia
Researchers from Fred Hutchinson Cancer Research Center in Seattle reported early results from a small study of their chimeric antigen receptor (CAR) T-cell product (JCAR014) in chronic lymphocytic leukemia (CLL) at the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition....
Expert Point of View: Prof. Noel Clarke, MBBS, FRCS, ChM
Formal discussant of the 111 trial, Prof. Noel Clarke, MBBS, FRCS, ChM, The Christie Hospital, Manchester, UK, had some concerns, but overall felt that the study could be practice-changing. “In this paper, single-cycle treatment is safe and effective, and two cycles of adjuvant BEP (bleomycin,...
One Cycle of BEP as Good as Two in High-Risk Testicular Cancer
The approach to treatment of high-risk, clinical stage I, nonseminomatous or combined germ cell tumors of the testis is not written in stone. Orchiectomy followed by surveillance or chemotherapy with two cycles of bleomycin, etoposide, and cisplatin (BEP) is a favored approach by most experts. A...
Two Studies Show Potential of Venetoclax as Single Agent and in Combination for Myeloma
Early-phase studies suggest that venetoclax (Venclexta) holds promise as a treatment for myeloma. At the 2016 American Society of Hematology (ASH) Annual Meeting & Exposition, investigators reported strong activity in heavily pretreated patients, especially those with the t(11;14)...
Different Subtypes of Acute Myeloid Leukemia Create Both Clinical and Research Challenges
Acute myeloid leukemia (AML) is the most common leukemia in adults. Each year, about 20,000 Americans will be diagnosed with AML, and roughly 10,000 people in this country will die of the disease. AML progresses quickly, and unless treatment begins soon and is effective , the prognosis is grim....
Cranberry
Scientific Name: Vaccinium macrocarpon Common Names: Mossberry, sassamanash, bounceberry Case Study M.C. is a 55-year-old woman with a history of stage I endometrial cancer, diagnosed and curatively treated 5 years ago. Since then, she has been having urinary tract infections from time to time....
Study Finds Link Between Telomere Length and Sociodemographic Circumstances Linked to Neighborhood
Researchers at Fox Chase Cancer Center have begun to establish a biologic basis for the long-held but not well-tested theory that neighborhood exposures can impact health outcomes. Shannon Lynch, PhD, MPH, Assistant Professor in the Cancer Prevention and Control Program at Fox Chase, led a team...
Progress in Defining Molecular Signature for Aggressive Androgen-Indifferent Prostate Cancer
Prostate cancer has lagged behind breast cancer in the identification of predictive and prognostic biomarkers, but the field is catching up. Researchers have identified a molecular signature that can distinguish aggressive prostate cancer that is androgen-indifferent and will have a better response ...
Conquer Cancer Foundation Recognizes Global Oncology Researchers With International Innovation Grant
The Conquer Cancer Foundation (CCF) of ASCO recently announced the recipients of its 2017 International Innovation Grant. The 1-year grant of up to $20,000, given directly to each awardee’s nonprofit organization or government agency, funds research projects aimed at improving cancer care in low-...
Pembrolizumab Active in Mucosal Melanoma in KEYNOTE Studies
Three clinical trials of the immunotherapy pembrolizumab (Keytruda) have shown that it is active against a rare subtype of skin cancer, mucosal melanoma. The findings were presented by Butler et al at the 2017 European Cancer Congress (ECCO).1 Mucosal melanoma has often been excluded from...
Breath Test Might Help Detect Stomach and Esophageal Cancers
A test that measures the levels of five chemicals in the breath has shown promising results for the detection of cancers of the esophagus and stomach, in a large patient trial presented by Markar et al at the 2017 European Cancer Congress (Abstract 6LBA).1 Together, stomach and esophageal cancers...
Onset of Diabetes or Its Rapid Deterioration Can Be an Early Warning Sign of Pancreatic Cancer
The onset of diabetes, or a rapid deterioration in existing diabetes that requires more aggressive treatment, could be a sign of early, hidden pancreatic cancer, according to research presented by Autier et al at the 2017 European Cancer Congress (Abstract 540).1 Study Design and Key Findings...
